Integrating computational and experimental chemical biology revealed variable anticancer activities of phosphodiesterase isoenzyme 5 inhibitors (PDE5i) in lung cancer-Reference-Cited by-同舟云学术

Integrating computational and experimental chemical biology revealed variable anticancer activities of phosphodiesterase isoenzyme 5 inhibitors (PDE5i) in lung cancer

Published:2024 Issue:8 Volume:15 Page:2882-2899
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Bardaweel Sanaa K.¹^ORCID,AlOmari Rola¹,Hajjo Rima²³⁴

Affiliation:

1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan

2. Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733, Jordan

3. Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

4. Board Member, Jordan CDC, Amman, Jordan

Abstract

PDE5 inhibition might suppress lung cancer cell growth by intertwining with various cancer cell signaling pathways, hinting at novel molecular roles for the PDE5 enzyme.

Funder

Deanship of Academic Research, University of Jordan

L'Oreal USA

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00364K

Reference68 articles.

1. Phosphodiesterase type 5 and cancers: progress and challenges

2. Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression

3. Over-expression of PDE5 in Oral Squamous Cell Carcinoma – Effect of Sildenafil Citrate

4. Inhibitors of phosphodiesterase as cancer therapeutics

5. The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels